ORIGINAL RESEARCH

COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in England

Alison E. Brown1,* | Sara E. Croxford1,* | Sophie Nash1 | Jameel Khawam1 | Peter Kirwan1,2 | Meaghan Kall1 | Daniel Bradshaw1 | Caroline Sabin3,4 | Robert F. Miller3,5 | Frank A. Post6 | Richard Harding7 | Simon Collins8,9 | Laura Waters5,9 | David Asboe9,10 | David R. Chadwick9,11 | Valerie Delpech1,** | Ann K. Sullivan1,9,10,**

1National Infection Service, Public Health England, London, UK
2Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK
3Institute for Global Health, University College London, London, UK
4National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Blood Borne and Sexually Transmitted Infections, University College London, London, UK
5Central and North West London NHS Foundation Trust, Mortimer Market Centre, London, UK
6King’s College Hospital NHS Foundation Trust, London, UK
7Florence Nightingale Faculty of Nursing Midwifery and Palliative Care, King’s College, London, UK
8HIV i-Base, London, UK
9British HIV Association, London, UK
10Directorate of HIV and Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
11South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK

Correspondence
Sara E. Croxford, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
Email: sara.croxford@phe.gov.uk

Abstract

Objectives: We describe COVID-19 mortality among people with and without HIV during the first wave of the pandemic in England.

Methods: National surveillance data on adults (aged ≥ 15 years) with diagnosed HIV resident in England were linked to national COVID-19 mortality surveillance data (2 March 2020–16 June 2020); HIV clinicians verified linked cases and provided information on the circumstances of death. We present COVID-19 mortality rates by HIV status, using negative binomial regression to assess the association between HIV and mortality, adjusting for gender, age and ethnicity.

Results: Overall, 99 people with HIV, including 61 of black ethnicity, died of/with COVID-19 (107/100 000) compared with 49 483 people without HIV (109/100 000). Compared to people without HIV, higher COVID-19 mortality
INTRODUCTION

Reliable ascertainment and description of mortality are critical in informing the public health response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which can lead to coronavirus disease (COVID-19). Examining the disparities in outcomes between population subgroups provides critical insight into which are the most severely affected, enabling the development of specific health policies to protect these populations.

In England, an estimated 96,200 people live with HIV, with 6% unaware of their infection [1]. Of those diagnosed, 98% receive antiretroviral treatment (ART) and of those on treatment, 97% are virally suppressed; this is equivalent to at least 89% of all people living with HIV in England having an undetectable viral load [1]. Although ART is effective in restoring immunity and uptake is high [2], persistent immune dysfunction and chronic inflammation may put people with HIV at increased risk of COVID-19 mortality due to a reduced ability to mount a protective immune response. Additionally, in England, people with HIV are more likely to be male and belong to communities known to experience socioeconomic deprivation, both of which are predictors of adverse COVID-19 outcomes [3,4]. Evidence on the risk of death from COVID-19 among people with HIV versus the general population is mixed, with some studies suggesting higher mortality rates [5–8] but others reporting little difference in mortality [9–11].

We use comprehensive national surveillance data to provide an epidemiological description of COVID-19 mortality among all people with diagnosed HIV during the first wave of the COVID-19 pandemic in England and compare the mortality burden to people without HIV.

METHODS

Data sources

People with HIV

As part of the national HIV surveillance programme, clinical and epidemiological information on all adults (aged ≥ 15 years) accessing HIV care in England is submitted to the HIV and AIDS Reporting System (HARS) at Public Health England (PHE) by National Health Service (NHS) specialist outpatient clinics [12]. Individual follow-up begins at diagnosis; data collected for each subsequent attendance for HIV outpatient care include: CD4 count (where indicated), HIV treatment status, HIV viral load and the presence of AIDS-defining illnesses.

Information on deaths among people with HIV (date and cause of death) are reported through routine surveillance, as well as through matching to mortality data from the Office for National Statistics (ONS). In 2019, PHE introduced enhanced surveillance of deaths among people with HIV (Annual National HIV Mortality Review) in collaboration with the British HIV Association (BHIVA) [13]. Briefly, HIV clinicians complete an online modified Causes of Death in HIV [14] reporting form for all deaths among their patients, which captures information on HIV clinical profile, comorbidities, lifestyle risk factors, causes of death and end-of-life care. Data are usually submitted annually and retrospectively. However, to better understand the impact of COVID-19 on people with HIV,
clinicians were contacted through the BHIVA network and asked to submit a mortality review form following each death of/with COVID-19 in a person with HIV.

General population

In England, COVID-19 deaths in the general population are reported to PHE daily through four sources: (1) the COVID-19 Patient Notification System (hospital deaths) [15]; (2) local PHE Health Protection Teams (deaths in non-hospital settings); (3) NHS Demographic Batch Service matching of all laboratory-confirmed COVID-19 cases against records of registered deaths; and (4) ONS death registration records. Data from each source are merged and de-duplicated, creating a single dataset [COVID-19 Specific Mortality Surveillance System (COSMOSS)].

Data linkage

The general population COVID-19 mortality dataset (data to 16 June 2020) was linked to the national HIV surveillance dataset using a combination of pseudo-anonymized identifiers [Soundex (scrambled surname) [19], first initial, date of birth, gender and lower super output area of residence] (PHE Caldicott approval: NISCRP552020). Two epidemiologists reviewed all matches independently, with disparities reviewed by an HIV clinician and consensus agreed. For matches deemed to be definite (exact matches for all information) or probable (matches for

| TABLE 1 | Mortality rates stratified by age group, HIV status and other demographics: England, 2 March to 16 June 2020 |
|---------|---------------------------------------------------------------|
| **People with HIV** | **All** | **15–59 years** | **≥ 60 years** |
| | Deaths | Population | Crude mortality rate per 100 000 | Deaths | Population | Crude mortality rate per 100 000 | Deaths | Population | Crude mortality rate per 100 000 |
| Total | 99 | 92 643 | 107 | 47 | 80 669 | 58.3 | 52 | 11 974 | 434 |
| Gender | | | | | | | | | |
| Men | 68 | 63 585 | 107 | 29 | 54 339 | 53.4 | 39 | 9 246 | 422 |
| Women | 31 | 28 978 | 107 | 18 | 26 252 | 68.6 | 13 | 2 726 | 477 |
| Region of residence | | | | | | | | | |
| London | 60 | 39 070 | 154 | 25 | 34 224 | 73.0 | 35 | 4 846 | 722 |
| South | 12 | 15 788 | 76.0 | 6 | 13 259 | 45.3 | 6 | 2 529 | 237 |
| Midlands | 19 | 20 166 | 94.2 | 11 | 17 583 | 62.6 | 8 | 2 583 | 310 |
| North | 8 | 17 605 | 45.4 | 5 | 15 589 | 32.1 | 3 | 2 016 | 149 |
| Ethnicity | | | | | | | | | |
| White | 32 | 48 526 | 65.9 | 13 | 40 528 | 32.1 | 19 | 7 998 | 238 |
| Black | 61 | 32 490 | 188 | 31 | 29 443 | 105 | 30 | 3 047 | 985 |
| Asian | 5 | 3821 | 131 | 2 | 3437 | 58.2 | 3 | 384 | 781 |
| Other/mixed | 1 | 5634 | 17.7 | 1 | 5232 | 19.1 | 0 | 402 | 0.0 |
| Index of multiple deprivation (IMD) | | | | | | | | | |
| 1 – most deprived | 33 | 30 235 | 109 | 16 | 27 078 | 59.1 | 17 | 3 157 | 538 |
| 2 | 31 | 24 488 | 127 | 15 | 21 520 | 69.7 | 16 | 2 968 | 539 |
| 3 | 21 | 14 671 | 143 | 8 | 12 460 | 64.2 | 13 | 2 211 | 588 |
| 4 | 11 | 9772 | 113 | 5 | 8154 | 61.3 | 6 | 1 618 | 371 |
| 5 – least deprived | 3 | 6331 | 47.4 | 3 | 5179 | 57.9 | 0 | 1 152 | 0.0 |
most information), clinicians were contacted by PHE and asked to confirm that the HIV patient had died and to submit the mortality review form (Figure S1). Where clinical information collected through the mortality review form conflicted with that collected in HARS (e.g. ART start date), the clinician-reported data were prioritized. For the five people with no mortality review form completed, HARS clinical profile data were used, where available.

Definition of COVID-19 mortality

People were considered to have died of/with COVID-19 if their death occurred within 60 days of a positive COVID-19 test [either polymerase chain reaction (PCR) (majority), nucleic acid amplification test (NAAT) or serological], with COVID-19 included on the ONS death registration form (death certificate), or if COVID-19 was reported as a cause of death by the reporting clinician.

Analyses

We present a descriptive analysis of adults with and without HIV resident in England who died of/with COVID-19 between 2 March and 16 June 2020 (3.5 months). There were no deaths reported among children aged < 15 years with HIV over this time period.

Crude mortality rates were calculated as the number of COVID-19 deaths per 100,000 population for those with and without HIV, comparing those aged 15–59 years with those aged ≥ 60. The number of adults living with diagnosed HIV in England at the end of 2019 (n = 92,643) was estimated as the number of people who accessed HIV outpatient care in 2019 (n = 88,341), plus: (1) people last seen for HIV outpatient care in 2018 and not known to have died by the end of 2019 (n = 3,580); and (2) those newly diagnosed with HIV in 2018 and 2019 but not yet seen for outpatient care (n = 722). The number of people without HIV was calculated by subtracting the number of people

| TABLE 1 (Continued) |
|---------------------|
| **People without HIV** | | | | |
| | **All** | **15–59 years** | **≥ 60 years** |
| | Deaths | Population | Crude mortality rate per 100 000 | Deaths | Population | Crude mortality rate per 100 000 | Deaths | Population | Crude mortality rate per 100 000 |
| | | | | | | | | | |
| 49,483 | 45,565,024 | 109 | 32,888 | 32,548,652 | 10.1 | 46,195 | 13,016,372 | 355 |
| 27,204 | 22,539,107 | 121 | 21,115 | 16,284,914 | 13.0 | 25,089 | 6,254,193 | 401 |
| 22,279 | 23,025,997 | 96.8 | 11,731 | 16,263,816 | 7.21 | 21,106 | 6,762,181 | 312 |
| 8,644 | 7,176,318 | 120 | 992 | 5,708,575 | 17.4 | 7,652 | 1,467,743 | 521 |
| 9,984 | 12,194,322 | 81.9 | 491 | 8,288,873 | 5.92 | 9,493 | 3,905,449 | 243 |
| 15,035 | 13,897,941 | 108 | 921 | 9,638,375 | 9.54 | 14,114 | 4,239,566 | 333 |
| 15,440 | 12,733,662 | 121 | 834 | 8,892,843 | 9.38 | 14,606 | 3,840,819 | 380 |
| 42,790 | 39,188,964 | 109 | 2,141 | 26,812,333 | 7.99 | 40,649 | 12,376,631 | 328 |
| 18,882 | 1,559,535 | 121 | 381 | 1,359,679 | 28.0 | 15,01 | 199,855 | 751 |
| 27,80 | 3,613,726 | 76.9 | 431 | 3,103,265 | 13.9 | 2,349 | 510,461 | 460 |
| 1,175 | 1,379,770 | 85.2 | 190 | 1,254,921 | 15.1 | 985 | 124,849 | 789 |
| 11,228 | 8,769,575 | 128 | 979 | 6,731,433 | 14.5 | 10,249 | 2,038,142 | 503 |
| 10,577 | 9,427,316 | 112 | 867 | 7,017,999 | 12.4 | 9,710 | 2,409,317 | 403 |
| 9,535 | 9,484,187 | 101 | 575 | 6,637,473 | 8.66 | 8,960 | 2,846,714 | 315 |
| 9,313 | 9,282,606 | 100 | 468 | 6,234,391 | 7.51 | 8,845 | 3,048,215 | 290 |
| 8,441 | 9,045,691 | 93.3 | 347 | 5,933,634 | 5.85 | 8,094 | 3,112,057 | 260 |
with HIV from the number of people in the general population (ONS) [20]. Latest available mid-year ONS population estimates were used: 2019 for IMD and region of residence and 2017 for ethnicity. Data were available by gender, age at death (5-year age bands) and ethnicity, region or IMD.

Multivariable negative binomial regression was used to assess the association between HIV and death of/with COVID-19, adjusting firstly for age at death and subsequently for gender, age at death and ethnicity. Interaction terms were added to assess effect modification by age and ethnicity. Separate models were built to describe associations between mortality and region of residence and IMD, adjusting for gender, age at death and HIV status.

We also describe the clinical profile of people with HIV who died of/with COVID-19 overall and by gender, age and ethnicity. Comorbidities reported to increase the risk of COVID-19 death include: cardiovascular disease (CVD) (including hypertension), diabetes mellitus, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), obesity and dementia/cognitive impairment [21]. Detailed information on comorbidities was available for those people with a completed mortality review form (n = 94); for the remainder, information on comorbidities was taken from the death certificate. Viral suppression was defined as a viral load of < 200 copies/mL. HIV viral load and CD4 count measurements were considered to be ‘at death’ if within a year of death.

All analyses were carried out using Stata v.15.0 (Stata Corp, College Station, TX, USA).

RESULTS

Mortality among people with and without HIV

As of 16 June 2020, there were 99 COVID-19 deaths reported among the 92 643 adults with diagnosed HIV in England, equivalent to a crude mortality rate of 107/100 000 population (Table 1). In comparison, there were 49 483 COVID-19 deaths reported among the 45 565 024 people without HIV over the same period, equivalent to a crude rate of 109/100 000.

Overall, the median age of death among people with HIV who died of/with COVID-19 was 60 years [interquartile range (IQR): 51–72], with 53% (52/99) aged ≥ 60. By comparison, median age of death among people without HIV who died with/ of COVID-19 was 83 years (IQR: 74–89), with 93% (46 195/49 483) aged ≥ 60. Sixty-nine percent (n = 68) of all COVID-19 deaths in people with HIV were among men, compared with 55% (n = 27 204) of those among people without HIV (Table 1). These differences largely reflect variation in the structure of the populations, whereby 13% (11 974/92 643) of all people with HIV were aged ≥ 60 and 69% (n = 63 585) were men compared with 29% (13 016 372/45 565 024) and 49% (n = 22 539 107) of those without HIV, respectively. Figure S2 shows the age and sex structure of both populations compared with the age and sex structure of those who died of/with COVID-19 and of any cause.

Higher crude mortality rates were observed among people aged ≥ 60 than among younger individuals (434 vs. 58.3/100 000 among people with HIV and 355 vs. 10.1/100 000 among those without) (Table 1). Crude mortality rates among people with HIV of black and Asian ethnicity were higher than those among people of equivalent ethnicity without HIV, and lower in the most deprived residential areas.

Risk factors for dying of/with COVID-19

After adjustment, the risk of COVID-19 death was 2.18 [95% confidence interval (CI): 1.76–2.70] times higher in people with HIV than in those without (Table 2). Regardless of HIV status, risk of death increased with increasing age [adjusted risk ratio (aRR) per increasing 5-year age band = 1.79, 95% CI: 1.77–1.81] and was higher in those of black (3.44, 95% CI: 3.06–3.87), Asian (2.24, 95% CI: 2.00–2.52) and other/mixed (3.23, 95% CI: 2.86–3.65) ethnicity, compared with those of white ethnicity. Women were less likely to die than were men (0.55, 95% CI: 0.51–0.60). There was no statistical evidence of interaction between HIV status and age or ethnicity. Separate models describing the association between region of residence and IMD on mortality can be found in Table S1.

Clinical characteristics of people with HIV who died of/with COVID-19

Table 3 shows the demographic and clinical characteristics of the 99 people with HIV who died of/with COVID-19; comparable data from the 96 243 people living with diagnosed HIV can be found in Table S2. Overall, 80% (n = 79) of people had a positive COVID-19 test prior to death, of whom 99% (n = 78) died within a month (28 days) of their positive test. This compares with 77% (n = 38 056) and 72% (n = 35 481) for deaths among those without HIV, respectively. Most people with HIV died in hospital [85% (84/99) vs. 64% (29 544/46 176) among those without HIV], while fewer died in a nursing home [9% (n = 9) vs. 30% (n = 13 664)].

The median time between HIV diagnosis and COVID-19-related death was 15 years (IQR: 10–19); three people...
died within 3 months of their HIV diagnosis and five within 1 year (Table 3). Access to outpatient specialist HIV care was high, with 95% (n = 94) attending at least once since their HIV diagnosis. Among those who accessed HIV care, 94% (n = 88) were last seen between 2018 and 2020, 5% (n = 5) were last seen between 2016 and 2017 and one person was last seen in 2002. The coverage of ART was 99% (n = 98) overall, with 94% (89/95) documented as receiving ART at death or in the preceding year [median time since ART initiation: 14 years (IQR: 9–18)]. Of the 69 people with a CD4 count reported in the year prior to death, 1.4% (n = 1), 16% (n = 11) and 42% (n = 29) had a CD4 count < 50, < 200 and < 350 cells/µL, respectively. Of those with a CD4 < 350 cells/µL, all were aged ≥ 40 years, 83% (n = 24) were ≥ 50 years old and 62% (n = 18) were ≥ 60. Of the 92 people with any CD4 count available, 14% (n = 13), 53% (n = 49) and 86% (n = 79) had a CD4 nadir < 50, < 200 and < 350 cells/µL, respectively. Overall, 91% (83/91) of people were virally suppressed. There were no significant differences by gender or ethnicity with regard to HIV clinical markers and ART uptake.

Ninety per cent (89/99) of people with HIV who died had at least one reported comorbidity; 87% (n = 82) had at least one documented comorbidity known to be associated with higher risk of poor COVID-19 outcomes (65% at least two) [21]. The prevalence of specific comorbidities was as follows: CVD (including hypertension), 69% (57/83); diabetes mellitus, 48% (40/83); CKD, 41% (32/78); COPD, 10% (8/77); and dementia/cognitive impairment, 17% (9/51). Among those with height and weight available (n = 70), 49% (n = 34) had a body mass index (BMI) of >30 kg/m² indicating obesity, and a further 26% (n = 18) were overweight (BMI 25–30 kg/m²). While diabetes mellitus was more common in men, obesity and dementia/cognitive impairment were more common in women. Diabetes mellitus, CVD, CKD and obesity were more common among

| Explanatory variables | Number of deaths | Adjusted risk ratio b | Adjusted risk ratio c |
|----------------------|------------------|----------------------|----------------------|
|                      |                  | aRR 95% CI p-value   | aRR 95% CI p-value   |
| Gender               |                  |                      |                      |
| Men                  | 27 272           | 1.00 – –             | 1.00 – –             |
| Women                | 22 310           | 0.56 0.45–0.69 < 0.001 | 0.55 0.51–0.60 < 0.001 |
| Age at death a       |                  |                      |                      |
| 15–19                | 13               | 1.80 1.75–1.85 < 0.001 | 1.79 1.77–1.81 < 0.001 |
| 20–29                | 80               |                      |                      |
| 30–39                | 226              |                      |                      |
| 40–49                | 726              |                      |                      |
| 50–59                | 2290             |                      |                      |
| 60–69                | 4840             |                      |                      |
| 70–79                | 11 120           |                      |                      |
| 80–89                | 19 542           |                      |                      |
| ≥ 90                 | 10 745           |                      |                      |
| Ethnicity            |                  |                      |                      |
| White                | 42 822           | 1.00 – –             | 1.00 – –             |
| Black                | 1943             | 3.89 3.14–4.78       | 3.44 3.06–3.87       |
| Asian                | 2785             | 2.25 1.82–2.77       | 2.24 2.00–2.52       |
| Other/mixed          | 1176             | 2.84 2.29–3.52 < 0.001 | 3.23 2.86–3.65 < 0.001 |
| Unknown              | 856              | – – – –             | – – – –             |
| HIV status           |                  |                      |                      |
| Without HIV          | 49 483           | 1.00 – –             | 1.00 – –             |
| With HIV             | 99               | 2.21 1.64–2.97 < 0.001 | 2.18 1.76–2.70 < 0.001 |

Abbreviations: aRR, adjusted risk ratio; CI, confidence interval.

aAge at death modelled as a continuous variable (increasing 5-year age bands).
bAdjusted for age at death and each explanatory variable (gender, HIV status or ethnicity).
cAdjusted for all explanatory variables (gender, age at death, HIV status and ethnicity).
dLikelihood ratio test.

TABLE 2 Risk factors associated with dying of/with COVID-19: England, 2 March to 16 June 2020
| TABLE 3 Characteristics of people with HIV who died of/with COVID-19 by gender and ethnicity: England, 2 March to 16 June 2020 |
|---------------------------------------------------------------|
| | All | Gender | | Ethnicity |
| | | Men | Women | White | Black | Otherf |
| | n | % | n | % | n | % | n | % | n | % |
| Total | 99 | | 68 | 31 | 32 | 61 | 6 |
| Age of death (years) [median (IQR)] | 60 (51–72) | 61 (53–74) | 55 (46–69) | 66 (50–77) | 59 (52–66) | 64 (40–73) |
| Year diagnosed with HIV | | | | | | | | | | |
| 2020 | 3 | 3.0% | 3 | 4.4% | 0 | 0% | 2 | 6.3% | 1 | 1.6% | 0 | 0% |
| 2018–2019 | 6 | 6.1% | 4 | 5.9% | 2 | 6.5% | 1 | 3.1% | 5 | 8.2% | 0 | 0% |
| 2006–2017 | 37 | 37% | 25 | 37% | 12 | 39% | 11 | 34% | 22 | 36% | 4 | 67% |
| < 2006 | 53 | 54% | 36 | 53% | 17 | 55% | 18 | 56% | 33 | 54% | 2 | 33% |
| Time living with diagnosed HIV (years) [median (IQR)] | 15 (10–19) | 15 (9–21) | 15 (11–18) | 15 (10–25) | 15 (10–18) | 13 (10–16) |
| Year last attended for HIV outpatient care prior to death if linked | | | | | | | | | | |
| 2020b | 28 | 30% | 17 | 27% | 11 | 35% | 11 | 37% | 16 | 28% | 1 | 17% |
| 2018–2019 | 60 | 64% | 40 | 63% | 20 | 65% | 15 | 50% | 41 | 71% | 4 | 67% |
| 2016–2017 | 5 | 5.3% | 5 | 7.9% | 0 | 0% | 3 | 10% | 1 | 1.7% | 1 | 17% |
| < 2016 | 1 | 1.1% | 1 | 1.6% | 0 | 0% | 1 | 3.3% | 0 | 0% | 0 | 0% |
| Ever on HIV treatment | 98 | 99% | 67 | 99% | 31 | 100% | 31 | 97% | 61 | 100% | 6 | 100% |
| Time since HIV treatment initiation (years) [median (IQR)] | 14 (9–18) | 14 (9–19) | 14 (10–17) | 14 (9–22) | 14 (9–18) | 12 (10–16) |
| HIV treatment at death | 89 | 94% | 59 | 91% | 30 | 100% | 26 | 87% | 58 | 97% | 5 | 100% |
| CD4 nadir (cells/µL) | | | | | | | | | | |
| < 50 | 13 | 14% | 6 | 10% | 7 | 23% | 2 | 6.9% | 11 | 19% | 0 | 0% |
| 50–199 | 36 | 39% | 21 | 34% | 15 | 48% | 10 | 34% | 23 | 40% | 3 | 50% |
| 200–349 | 30 | 33% | 24 | 39% | 6 | 19% | 10 | 34% | 17 | 30% | 3 | 50% |
| 350–499 | 7 | 7.6% | 5 | 8.2% | 2 | 6.5% | 3 | 10% | 4 | 7.0% | 0 | 0% |
| ≥ 500 | 6 | 6.5% | 5 | 8.2% | 1 | 3.2% | 4 | 14% | 2 | 3.5% | 0 | 0% |

(Continues)
| CD4 count at death (cells/µL)\(^c\) | All | Men | Women | Ethnicity |
|---|---|---|---|---|
|  | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % |
| < 50 | 1 | 1.4% | 1 | 2.2% | 0 | 0% | 1 | 4.8% | 0 | 0.0% | 0 | 0% |
| 50–199 | 10 | 14% | 9 | 20% | 1 | 4.3% | 4 | 19% | 6 | 13% | 0 | 0% |
| 200–349 | 18 | 26% | 10 | 22% | 8 | 35% | 7 | 33% | 9 | 20% | 2 | 67% |
| 350–499 | 18 | 26% | 14 | 30% | 4 | 17% | 4 | 19% | 13 | 29% | 1 | 33% |
| ≥ 500 | 22 | 32% | 12 | 26% | 10 | 43% | 5 | 24% | 17 | 38% | 0 | 0% |

| Viral load measurement at death (copies/mL)\(^c\) | All | Men | Women | Ethnicity |
|---|---|---|---|---|
|  | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % |
| < 50 | 74 | 81% | 49 | 80% | 25 | 83% | 22 | 79% | 48 | 83% | 4 | 80% |
| 50–199 | 9 | 10% | 6 | 9.7% | 3 | 10% | 2 | 7.1% | 6 | 10% | 1 | 20% |
| 200–1499 | 1 | 1.1% | 1 | 1.6% | 0 | 0% | 0 | 0.0% | 1 | 1.7% | 0 | 0% |
| ≥ 1500 | 7 | 7.7% | 5 | 7.8% | 2 | 6.7% | 4 | 14% | 3 | 5.2% | 0 | 0% |

| Comorbidities\(^d\) | All | Men | Women | Ethnicity |
|---|---|---|---|---|
|  | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % | \(n\) | % |
| Any comorbidity | 89 | 90% | 62 | 91% | 27 | 87% | 27 | 84% | 56 | 92% | 6 | 100% |
| Any COVID−19 comorbidity\(^e\) | 82 | 87% | 56 | 82% | 26 | 84% | 22 | 69% | 55 | 90% | 5 | 83% |
| CVD (including hypertension) | 57 | 69% | 42 | 70% | 15 | 65% | 14 | 56% | 38 | 72% | 5 | 100% |
| Hypertension | 32 | 39% | 24 | 40% | 8 | 35% | 5 | 20% | 26 | 49% | 1 | 20% |
| Diabetes mellitus | 40 | 48% | 31 | 52% | 9 | 39% | 8 | 33% | 28 | 52% | 4 | 80% |
| COPD | 8 | 10% | 5 | 9.3% | 3 | 13% | 5 | 22% | 3 | 6.0% | 0 | 0% |
| CKD | 32 | 41% | 22 | 40% | 10 | 43% | 6 | 25% | 22 | 44% | 4 | 100% |
| Obesity | 34 | 49% | 19 | 42% | 15 | 60% | 6 | 29% | 27 | 42% | 1 | 60% |
| Dementia/cognitive impairment | 9 | 18% | 5 | 15% | 4 | 22% | 4 | 27% | 5 | 15% | 0 | 0% |

Note: Proportions may not add up to 100% due to rounding.

1 month = 28 days; 3 months = 91 days; 1 year = 365 days.

Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; IQR, interquartile range.

\(^a\)80% \((n = 79)\) of people with HIV who died of/with COVID-19 were confirmed (positive SARS-CoV-2 test result).

\(^b\)Data for 2020 not complete – up to mid-June 2020.

\(^c\)Measured within a year of death for people who died of/with COVID-19.

\(^d\)Detailed information available for those people with a mortality review form completed \((n = 94)\); for the remainder, information on comorbidities was taken from the death certificate.

\(^e\)Conditions more common in people who died of/with COVID-19 compared with other causes [21].

\(^f\)Other ethnicity: Asian and other/mixed.
people of black ethnicity than among those of white ethnicity (Table 3).

Table 4 presents the burden of comorbidities known to be associated with poor COVID-19 outcomes among people with diagnosed HIV who died of/with COVID-19 by gender, age at death and ethnicity. Of the 47 people who died aged < 60, 74% had at least one documented comorbidity associated with poor COVID-19 outcomes; 55% had two or more comorbidities and 19% had one. This compares with 96% among the 25 people who died age 60–69 years (80% had two or more comorbidities and 16% had one) and 85% among the 27 people who died aged ≥ 70 (70% had two or more and 15% had one). Among the 12 people aged < 60 years with no documented comorbidities, three were not virally suppressed within a year of death. The prevalence of comorbidities was high for both men and women, and across ethnicities.

**DISCUSSION**

We describe COVID-19 mortality among people with diagnosed HIV during the first wave of the pandemic in England. The overall mortality rate due to COVID-19 among people with HIV was low, at approximately 0.1%. Whilst this low death rate is reassuring, it is possible that a relatively small proportion of the population (particularly those with HIV) was exposed to the virus during the first 3.5 months of the pandemic [22]. United Kingdom government advice to ‘stay at home’ and ‘socially distance’ was released in March and specific groups of the population, identified as clinically extremely vulnerable, were asked to ‘shield’ by staying home for 3 months and avoid all non-household contacts [23]. People with HIV were initially included in the government’s shielding advice; however this was subsequently changed in line with advice issued by BHIVA in late April.

| Age and comorbidity profile | All | Gender |
|-----------------------------|-----|--------|
|                             |     |        |
|                             | Number of people affected | Cumulative categorization | Number of people affected | Cumulative categorization | Number of people affected | Cumulative categorization |
|                             | n    | %     | n    | %     | n    | %     | n    | %     | n    | %     |
| Age at death ≥ 70 years     | 27   | 27%   | –    | –     | 20   | 29%   | –    | –     | 7    | 23%   |
| Two or more documented comorbidities | 19 | 70% | 19 | 70% | 15 | 75% | 15 | 75% | 4 | 57% |
| One documented comorbidity  | 4    | 15%   | 23   | 85%   | 3    | 15%   | 18   | 90%   | 1    | 14%   | 5    | 71%   |
| Age at death 60–69 years    | 25   | 25%   | –    | –     | 19   | 28%   | –    | –     | 6    | 19%   | –    | –     |
| Two or more documented comorbidities | 20 | 80% | 20 | 80% | 14 | 74% | 14 | 74% | 6 | 100% |
| One documented comorbidity  | 4    | 16%   | 24   | 96%   | 4    | 21%   | 18   | 95%   | 0    | 0%    | 6    | 100%   |
| Age at death < 60 years     | 47   | 47%   | –    | –     | 29   | 43%   | –    | –     | 18   | 58%   | –    | –     |
| Two or more documented comorbidities | 26 | 55% | 26 | 55% | 17 | 59% | 17 | 59% | 9 | 50% |
| One documented comorbidity  | 9    | 19%   | 35   | 74%   | 3    | 10%   | 20   | 69%   | 6    | 33%   | 15   | 83%   |

Note: Proportions may not add up to 100% due to rounding.

| Cardiac disease (including hypertension), diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, dementia/cognitive impairment, obesity. |
| Information available for those people with a mortality review form completed (n = 94) and the two additional people who had relevant comorbidities listed on the death certificate. |
| Other ethnicity: Asian and other/mixed. |
recommending that only individuals with CD4 counts < 50 cells/µL, a recent AIDS diagnosis and/or multiple comorbidities should ‘shield’ [24]. Consequently, the risk of death among those most clinically vulnerable with HIV may be underestimated in our study.

Although mortality was low overall, COVID-19 mortality among people with HIV in England was more than double that of people without HIV after differences in the population age structure were taken into consideration. This is consistent with other published studies [5–8]. Primary care data from the OpenSAFELY platform showed people living with HIV had higher risk of COVID-19 death (hazard ratio = 2.90, 95% CI: 1.96–4.30) than those without HIV after adjusting for age and sex [5]. The ISARIC study of a subset of patients hospitalized with COVID-19 in the UK found a 63% increased risk of mortality among those with HIV compared with HIV-negative individuals after adjusting for sex, ethnicity, age, baseline date, comorbidities and disease severity at presentation [8]. Similar to these other studies, our findings should be interpreted with caution [25]. Unlike OpenSAFELY and ISARIC, which were restricted to analysis of specific subgroups (e.g. people registered at general practice or in hospital), we utilized comprehensive national HIV surveillance data including all people living with diagnosed HIV and had access to data on all people who died of/with COVID-19 in the general population. Nevertheless, we were limited by a lack of available data on comorbidities for those without HIV to adjust our analyses; this is particularly important as people with HIV are known to have higher levels of comorbidities than the general population [3,26].

Our analyses show that among people with HIV who died of/with COVID-19, the large majority (88%) were either

| Ethnicity | White | Black | Other |
|-----------|-------|-------|-------|
| Number of people affected | Cumulative categorization | Number of people affected | Cumulative categorization | Number of people affected | Cumulative categorization |
| n  | %  | n  | %  | n  | %  | n  | %  |
| 14  | 44% | 10  | 16% | 3  | 50% |
| 9   | 64% | 7   | 70% | 3  | 43% |
| 2   | 14% | 2   | 20% | 0  | 0%  |
| 5   | 16% | 20  | 33% | 0  | 0%  |
| 3   | 60% | 17  | 85% | 0  | 0%  |
| 1   | 20% | 3   | 80% | 0  | 0%  |
| 13  | 41% | 31  | 51% | 3  | 50% |
| 4   | 31% | 20  | 65% | 2  | 67% |
| 3   | 23% | 6   | 19% | 0  | 0%  |

Note: Proportions may not add up to 100% due to rounding.

*Cardiovascular disease (including hypertension), diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, dementia/cognitive impairment, obesity.

Information available for those people with a mortality review form completed (n = 94) and the two additional people who had relevant comorbidities listed on the death certificate.

*Other ethnicity: Asian and other/mixed.
aged ≥ 60 (53%) or had at least one documented comorbidity known to be a risk factor for COVID-19 death (87%). There were very few deaths among people with diagnosed HIV aged < 60 without a documented comorbidity. The comorbidities commonly reported among people with HIV who died of/with COVID-19 in England included CVD (69%), obesity (49%), diabetes mellitus (48%), CKD (41%) and hypertension (39%). These rates are higher than those reported among all people living with diagnosed HIV (Table S2) [3,26], higher than those documented among people with HIV who died pre-COVID-19 and higher than the general population as a whole [27,28]. These findings are consistent with the literature and highlight the importance of ensuring optimal care of comorbidities alongside HIV care [29–32].

Over two-thirds of the people with HIV who died of/with COVID-19 were from black, Asian or ethnic minority populations; only 35% of people living with diagnosed HIV in England are of these ethnicities. We observed a higher risk of COVID-19 mortality in people of an ethnic minority with HIV, compared with those without, remained after adjustment for age and gender. Higher COVID-19 diagnosis rates have been observed among people of black ethnic groups in England than among other ethnic groups, as well as higher mortality rates [21,33]. This disparity may be partially explained by socioeconomic factors, comorbidities and occupational exposure to COVID-19, with a relatively high proportion of people of black ethnicity employed in health and social care roles [32,34,35]. Our ability to characterize the relationship between ethnicity and mortality was limited by a lack of data on underlying COVID-19 testing and diagnosis rates and an inability to adjust for occupational exposure. Furthermore, despite finding that an increased risk of death was seen among those in London and those living in areas of higher deprivation (Table S1), we could not adjust for ethnicity, IMD and region of residence in the same model, due to a lack of available general population data.

This is the first population-level national study of COVID-19 mortality among people with HIV in the UK, capturing all deaths during the first wave. We linked the national cohort of people diagnosed with HIV to national COVID-19 death data, including people not linked to HIV care and those lost to clinical follow up, groups that may be particularly vulnerable to COVID-19. Additional clinical data were collected on those who died to ascertain the treatment and immunosuppression levels, as well as better understand comorbidities and cause of death. PHE reports to date have focused on people who have died within 28 and 60 days of a positive COVID-19 test or linked to a death registration certificate [36]. We also included deaths where COVID-19 was entered on the death certificate of individuals who were not linkable to a positive COVID-19 test; most of these deaths occurred at the start of the pandemic where testing was not widely available.

However, our study has several additional limitations. Mortality rates among people with HIV presented here exclude deaths among the 5900 people estimated to have undiagnosed infection in England; however, this is a relatively low proportion (6%) among all people with HIV in the country [1]. We are not yet able to calculate excess mortality as surveillance of deaths among people with HIV in 2020 is still under way. We cannot calculate case fatality or account for any differences in exposure to COVID-19 comparing HIV and those without [37]. Despite HIV surveillance being comprehensive and of high quality, there were some missing data which may have affected our findings. Notably, CD4 counts in the year preceding death were only available for 70% of people who died of/with COVID-19; this reflects current UK monitoring guidelines which do not require annual CD4 testing for those with well-controlled HIV [38]. COVID-19 is known to dysregulate the immune system and lower CD4 cell counts [39]; in our analysis we included at least 17 people with a CD4 measured within 2 weeks of or after their COVID-19 diagnosis. However, this should have minimal impact as the distribution of these counts was equitable across CD4 strata (Table 3). Where clinical information collected through the mortality review form conflicted with that collected in HARS, clinician-reported data were prioritized. However, clinicians may not have been aware of previous clinical history if patients died in hospitals where they did not receive HIV outpatient care. Our analysis includes data until June 2020. In England, COVID-19 deaths remained at low sustained levels through the summer months of 2020 before rising again in late September [18]. Over 65 000 additional COVID-19 deaths in the general population were reported to PHE as of 15 February 2021. However, the age, sex and ethnic profile of people who died has not changed substantially over this period and thus we believe the results presented remain representative and relevant across the pre-vaccination era [18].

**CONCLUSIONS**

In England, where 94% of people with HIV are diagnosed and on suppressive ART, the rate of COVID-19 mortality in the first wave of the COVID-19 pandemic among people with HIV was low but higher than among those without HIV after controlling for age. Few people with HIV who died of/with COVID-19 were aged < 60 and did not have a documented comorbidity associated with worse outcomes. Most people with HIV who died of/with COVID-19 had risk factors similar to those identified in the general population; male, older age, non-white ethnicity, comorbid conditions and residential deprivation are important risk factors for COVID-19 mortality regardless of HIV status. People with HIV in the UK are currently...
being prioritized for COVID-19 vaccination [40]. Our findings highlight that uptake of vaccination in people with HIV of all ages should be strongly encouraged.

ACKNOWLEDGEMENTS
We gratefully acknowledge the continuing collaboration of people living with HIV, as well as clinicians, microbiologists, immunologists, public health practitioners, occupational health doctors, nurses and other colleagues who contribute to the surveillance of HIV in the UK. We also acknowledge the hard work of the PHE COVID-19 Epidemiology Cell in pulling together the death data.

CONFLICT OF INTEREST
SEC, AEB, SN, MK, AKS, PK, JK, VD and SC have no conflicts of interest to declare. DB reports grants from ViiV Healthcare and Gilead Sciences outside the submitted work. LW reports speaker/advisory fees from Gilead Sciences, Viiv Healthcare, Merck Sharp & Dohme (MSD), Janssen-Cilag, Cipla, Mylan and Theratechnologies and funding for clinical trials from Gilead Sciences and Janssen-Cilag outside the submitted work. FAP reports grants and personal fees from Gilead Sciences, Viiv Healthcare, Janssen-Cilag and MSD outside the submitted work. RFM reports personal fees from Gilead Sciences for conference attendance and non-promotional talks outside the submitted work. CS reports funding from Gilead Sciences and Janssen-Cilag for participation in advisory panels and for the preparation of educational materials outside the submitted work. DRC reports funding from Gilead Sciences and Viiv Healthcare for the preparation of educational materials and research grants outside the submitted work. RH reports educational consultancies from Gilead Sciences and Viiv Healthcare outside the submitted work. DA reports advisory fees from Gilead Sciences and Viiv Healthcare outside the submitted work.

AUTHOR CONTRIBUTIONS
VD, DB, AEB, AKS and SEC conceived this research study. AEB extracted data on COVID-19 deaths in the general population. JK and SN extracted the HIV data and JK performed the data linkage. SEC and AEB reviewed all matches; AKS reviewed all discrepancies. SEC and AKS coordinated mortality review form follow-up. FAP, RFM and SEC reviewed all causes of death. SEC and AEB carried out the majority of analyses and drafted and finalized the paper; SN carried out the descriptive analysis of people with HIV. CS and PK provided input into the research methods as well as statistical support. MK, DB, CS, RFM, FAP, RH, SC, LW, DA, DRC, VD and AKS provided important intellectual content to the discussion and conclusions. All authors critically appraised the manuscript and approved its submission.

ORCID
Alison E. Brown https://orcid.org/0000-0002-6490-6739
Sara E. Croxford https://orcid.org/0000-0003-2220-623X
Sophie Nash https://orcid.org/0000-0002-7717-6982
Peter Kirwan https://orcid.org/0000-0001-6904-0500
Meaghan Kall https://orcid.org/0000-0001-6971-427X
Daniel Bradshaw https://orcid.org/0000-0001-7186-2482
Caroline Sabin https://orcid.org/0000-0001-5173-2760
Robert F. Miller https://orcid.org/0000-0003-2067-4291
Frank A. Post https://orcid.org/0000-0002-2844-1612
Richard Harding https://orcid.org/0000-0001-9653-8689
Simon Collins https://orcid.org/0000-0002-3537-2432
Laura Waters https://orcid.org/0000-0002-1379-1775
David R. Chadwick https://orcid.org/0000-0002-7955-9610
Valerie Delpech https://orcid.org/0000-0002-9952-8109

REFERENCES
1. Public Health England. Trends in HIV testing, new diagnoses and people receiving HIV-related care in the United Kingdom: data to the end of December 2019. PHE; 2020.
2. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335-343.
3. Public Health England. Positive voices: the national survey of people living with HIV: findings from the 2017 survey. PHE; 2020.
4. Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11:6317.
5. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2020;8:E24-E32.
6. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
7. Boulle A, Davies MA, Hussey H, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2020;ciaa1198.
8. Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO clinical characterisation protocol (UK): a prospective observational study. Clin Infect Dis. 2020;ciaa1605.
9. Sigel K, Swartz T, Golden E, et al. COVID-19 and people with HIV infection: outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;71:2933-2938.
10. Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7:e314-e316.
11. Inciarne A, Gonzalez-Cordon A, Rojas J, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS. 2020;34:1775-1780.
12. Public Health England. HIV surveillance systems [online]. 2020. https://www.gov.uk/guidance/hiv-surveillance-systems. Accessed March 15, 2021.
13. British HIV Association. Annual National HIV Mortality Review [online]. 2020. https://www.bhiva.org/NationalHIVMortalityReview. Accessed March 15, 2021.

14. Kowalska JD, Friis-Møller N, Kirk O, et al. The coding causes of death in HIV (CoDe) project: initial results and evaluation of methodology. *Epidemiology*. 2011;22:516-523.

15. Public Health England. PHE data series on deaths in people with COVID-19: technical summary [online]. 2020. https://www.gov.uk/government/publications/phe-data-series-on-deaths-in-people-with-covid-19-technical-summary. Accessed March 15, 2021.

16. Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in March 2020 [online]. 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingcovid19inenglandandwales/deathstoccurringinmarch2020. Accessed March 15, 2021.

17. Ministry of Housing, Communities and Local Government. Fast Track Cities [online]. 2021. https://www.gov.uk/government/publications/ftc-technical-summary-2021. Accessed March 15, 2021.

18. Brown AE, Heinsbroek E, Kall MM, et al. Epidemiology of confirmed COVID-19 deaths in adults, England, March-December 2020. *Emerg Infect Dis*. 2021;27:1468-1471.

19. Mortimer JY, Salathiel JA. ‘Soundex’ codes of surnames provide confidentiality and accuracy in a national HIV database. *Commun Dis Rep CDR Rev*. 1995;5:R183-R186.

20. Office for National Statistics. Population estimates 2019 [online]. 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates. Accessed March 15, 2021.

21. Public Health England. *Disparities in the risk and outcomes of COVID-19*. PHE; 2020.

22. Office for National Statistics. Antibodies against coronavirus (COVID-19) [online]. 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights#antibodies. Accessed March 15, 2021.

23. UK Government Cabinet Office. Guidance: Staying alert and safe (social distancing) [online]. 2020. https://www.gov.uk/government/publications/staying-alert-and-safe-social-distancing/staying-alert-and-safe-social-distancing. Accessed March 15, 2021.

24. British HIV Association. COVID-19 and shielding: advice for HIV clinicians, GPs and people living with HIV [online]. 2020. https://www.bhiva.org/COVID-19-and-shielding-advice-for-HIV-clinicians-GPs-and-people-living-with-HIV. Accessed March 15, 2021.

25. Waters LJ, Pozniak AL. COVID-19 death in people with HIV: interpret cautiously. *Lancet HIV*. 2021;8:e2-e3.

26. Public Health England. *Positive voices 2017: data tables*. PHE; 2020.

27. Croxford S, Miller RF, Post FA, et al. Mortality and causes of death among HIV patients in London in 2017. *Fast Track Cities conference*. United Kingdom; 2019.

28. Health and Social Care Information Centre (NHS Digital). *Quality and outcomes framework 2019–20: prevalence, achievement and personalised care adjustments - regional and national level*. NHS Digital; 2020.

29. Dandachi D, Geiger G, Montgomery MW, et al. Characteristics, comorbidities, and outcomes in a multicity registry of patients with HIV and coronavirus disease-19. *Clin Infect Dis*. 2020;ciaa1339.

30. Meyerowitz EA, Kim AY, Ard KL, et al. Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV. *AIDS*. 2020;34:1781-1787.

31. Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients with HIV: a multi-center research network study. *AIDS*. 2020;34:F3-F8.

32. Public Health England. *Analysis of the relationship between pre-existing health conditions, ethnicity and COVID-19*. PHE; 2020.

33. Childs K, Post FA, Norcross C, et al. Hospitalized patients with COVID-19 and human immunodeficiency virus: a case series. *Clin Inf Dis*. 2020;71:2021-2022.

34. Platt L, Warwick R. *Are some ethnic groups more vulnerable to COVID-19 than others*. Institute of Fiscal Studies, Nuffield Foundation; 2020.

35. Mutambudzi M, Niedwiedz C, Macdonald EB, et al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. *Occup Environ Med*. 2021;78:307–314.

36. Public Health England. *Weekly coronavirus disease 2019 (COVID-19) surveillance report*. London. PHE; 2020.

37. Harman K, Allen H, Kall M, Dabrera G. Interpretation of COVID-19 case fatality risk measures in England. *J Epidemiol Community Health*. 2021;75:415–416.

38. British HIV Association. *BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals (2019 interim update)*. BHIVA; 2019.

39. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients With coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis*. 2020;71:762-768.

40. UK government. *COVID-19 vaccination first phase priority groups* [online]. 2021. https://www.gov.uk/government/publications/covid-19-vaccination-care-home-and-healthcare-settings-posters/covid-19-vaccination-first-phase-priority-groups. Accessed March 15, 2021.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.